# Frontera Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/frontera-therapeutics

- Industry: Biotechnology
- Headquarters: US
- Website: www.fronteratherapeutics.com
- Total disclosed funding: $195M
- Latest round: Series B (Jul 19, 2022)
- Investors on record: 7

## About

Based in Massachusetts, US, and founded in 2019, Frontera Therapeutics operates as a developer of gene therapy products. The company's founder and CEO, Yong Dai graduated from Peking University and he recently served as the Chief Technology Officer at Prevail Therapeutics. The company has an operation center in Shanghai and an R&D center in Boston.

The company has developed an adeno-associated virus (AAV) gene expression system named APEX Technology & Manufacturing Platform. The platform includes validated AAV vectors, CMC processes, and early clinical data. The company also designs AAV gene therapy vectors to increase expression, enhance activity, and reduce immunogenicity. The company's pipelines include orphan diseases, ophthalmology, hematology, neuromuscular and metabolic diseases.

## Funding rounds

- Series B, Jul 19, 2022, $160M — OrbiMed Advisors, Hong Shan, Boyu Capital, Starr Investment Holdings, 6 Dimensions Capital, Loyal Valley Capital, Creacion Ventures
- Series A, Feb 4, 2021, $35M — OrbiMed Advisors, 6 Dimensions Capital

## Investors

- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Series A, Series B
- 6 Dimensions Capital (https://capitalatlas.ai/funds/6-dimensions-capital) — Series A, Series B
- Hong Shan — Series B
- Boyu Capital (https://capitalatlas.ai/funds/boyu-capital) — Series B
- Starr Investment Holdings (https://capitalatlas.ai/funds/starr-investment-holdings) — Series B
- Loyal Valley Capital (https://capitalatlas.ai/funds/loyal-valley-capital) — Series B
- Creacion Ventures (https://capitalatlas.ai/funds/creacion-ventures) — Series B